KOL Tiering

KOL tiering is the practice of ranking key opinion leaders (KOLs) into groups usually Tier 1, Tier 2, and Tier 3 based on their scientific influence, so medical affairs and commercial teams can match the intensity of engagement to how much impact each KOL actually has.

What Is KOL Tiering?

KOL tiering is how pharmaceutical and medical device companies sort key opinion leaders into ranked groups based on influence, rather than treating every KOL relationship the same way. A KOL with global publication reach and frequent guideline authorship gets a different engagement plan than an emerging voice with local, single-region influence — tiering is the framework that makes that distinction explicit and repeatable across a medical affairs team.

Tiering comes after KOL identification — first you find the right experts, then you rank them. Without that second step, engagement tends to default to whoever's easiest to reach, not whoever has the most influence. That's the practical problem tiering solves.

Why Medical Affairs Teams Tier KOLs

Two forces drive the practice.

Resource allocation. MSL teams typically can't give equal attention to every KOL in a therapeutic area. Tiering lets a team concentrate its scarcest resources — Chief Medical Officer or Head of Medical involvement, early advisory board seats, clinical trial or publication collaboration — on the KOLs whose influence justifies it, while maintaining lighter-touch relationships with everyone else.

Consistency and compliance. When tiers rest on documented criteria rather than personal relationships, engagement decisions become easier to justify internally. The PhRMA Code on Interactions with Health Care Professionals points the same way: it says decisions about selecting health care professionals as consultants or speakers should rest on defined criteria such as medical expertise, reputation, and therapeutic-area experience — and that compensation should reflect fair market value, not the volume or value of business that professional generates.

The Standard KOL Tiering Model: Tier 1, 2, and 3

Most medical affairs teams use a three-tier structure, though exact labels and cutoffs vary by company and therapeutic area.

• Tier 1 — Global or National KOLs. High-impact publication history, frequent speaking engagements, guideline-committee involvement, and influence extending across countries or an entire national market. Tier 1 KOLs are the ones a CMO or Head of Medical Affairs is likely to meet with directly, and they're often approached for advisory boards as early as Phase 1.
• Tier 2 — Regional KOLs. Moderate publication impact and speaking activity, with influence concentrated at the regional or multi-site level rather than nationally or globally.
• Tier 3 — Emerging or Local KOLs. Local influence, often earlier-career or specialty-specific voices, tracked for how quickly their influence is growing. Tier 3 assignments use the same scientific-influence criteria as Tier 1 and 2, just at a smaller scale — the difference is reach and volume of activity, not a different measurement approach.

Criteria Used to Tier a KOL

Tiering models differ by company, but the criteria that show up consistently include:

• Publication record — volume, recency, and citation impact of peer-reviewed work
• Clinical trial involvement — principal investigator or steering committee roles
• Guideline and consensus panel participation
• Speaking and advisory activity — frequency and reach of presentations, advisory boards, congress panels
• Geographic scope of influence — local, regional, national, or global
• Digital reach — increasingly tracked separately as Digital Opinion Leader (DOL) influence, since a KOL's scientific standing and social/digital reach don't always move together
• Relationship and engagement history — the existing depth of the company's own relationship with that KOL

One input that's often assumed to belong on this list but usually doesn't: prescribing volume. Most medical affairs-led tiering frameworks treat scientific and clinical influence as the primary basis for a tier, with prescribing volume as a secondary signal at most — a high-volume prescriber isn't automatically a thought leader, and a lower-volume researcher with guideline authorship can outrank them. There is a compliance reason for that as well as a strategic one: the PhRMA Code states that consulting and speaking arrangements should be neither inducements nor rewards for prescribing. A tiering model built on script data invites exactly the inference the Code warns against. For engagement planning — which tier gets a CMO meeting, an advisory board seat, a co-authorship pitch — scientific influence is the criterion that holds up.

No single criterion determines a tier on its own — it's the combination that produces a defensible ranking.

KOL Tiering vs. Identification, Mapping and Segmentation

Four terms, constantly used interchangeably, describing four different jobs. The quickest way to keep them straight is the question each one answers.

• KOL identification — who are the experts? Discovering the clinicians and researchers who hold influence in a therapeutic area.
• KOL mapping — how are they connected? Charting the relationships between them: co-authorship links, shared institutions, society and guideline-committee overlap, and who refers or defers to whom.
• KOL segmentation — what kind of value does each one bring? Grouping by type rather than rank — a clinical-trial-focused KOL versus a guideline-committee KOL versus a digital- or social-first KOL.
• KOL tiering — who gets which level of engagement? Ranking those experts by influence so effort matches impact.

In practice these run in sequence, and the order matters. Identification without mapping gives you a list with no sense of how influence travels through it — a moderately published KOL sitting at the centre of a referral network can matter more than a heavily published one working in isolation. Most medical affairs teams then segment before they tier: understand what kind of value a KOL brings first, then rank within each segment to set engagement intensity.

How Tiering Changes Engagement Strategy

Tier assignment should drive concrete differences in how a team engages, not just an internal label:

• Tier 1: senior leadership involvement, early advisory board inclusion, higher-frequency touchpoints, publication or co-authorship collaboration
• Tier 2: regular MSL engagement, congress and regional advisory board participation
• Tier 3: lighter-touch, often digital-first engagement, monitored for tier progression as influence grows

Reviewing tier assignments on a set cadence — many teams do this annually or per launch cycle — matters because influence shifts. A Tier 3 KOL who publishes a high-impact study or takes on a guideline-committee role can move up quickly, and tiering models that aren't revisited miss that. A documented KOL engagement planning framework makes that review cadence easier to keep on schedule.

Common Mistakes in KOL Tiering

• Tiering once and never revisiting it — influence changes, and static tiers age quickly
• Using accessibility as a proxy for tier — the easiest KOL to reach isn't necessarily the most influential one
• Conflating tiering with segmentation — treating "Tier 1" as a catch-all for "important" without defining what kind of influence qualifies
• Tiering without documentation — undocumented criteria make tier assignments hard to defend internally

How TikaMobile Supports KOL Tiering

KOL tiering is only as reliable as the data underneath it. Publication activity, engagement history, advisory board participation, interaction outcomes — when those sit in scattered spreadsheets and individual MSLs' notes, tier assignments end up reflecting whoever knows a given KOL best rather than documented influence. TikaMSL's KOL management module centralises that layer — KOL relationship tracking, engagement planning, insight capture and interaction outcomes in one system — so every MSL is working from the same record when tiers are set and reviewed.

FAQ

What's the difference between Tier 1 and Tier 2 KOLs?

Tier 1 KOLs typically have national or global influence — high publication output, guideline involvement, and frequent speaking engagements — while Tier 2 KOLs have similar but more regionally concentrated influence, usually with a smaller publication and speaking footprint.

Is KOL tiering the same as KOL segmentation?

No. Tiering ranks KOLs by influence level (Tier 1, 2, 3). Segmentation groups KOLs by the type of value they provide, such as clinical trial leadership versus digital/social influence. Many teams use both together.

How often should KOL tiers be reviewed?

Most medical affairs teams reassess tiering annually or aligned to a product launch cycle, since a KOL's influence — new publications, guideline roles, advisory positions — can shift meaningfully within a year.

Does prescribing volume factor into KOL tiering?

Not directly, in most medical affairs-led frameworks. Scientific and clinical influence — publications, trial involvement, guideline roles — is the primary basis for a tier; prescribing volume is treated as a secondary signal at most, since high prescribing activity doesn't necessarily reflect scientific influence. Compliance-focused tools built for fair-market-value compensation sometimes weight prescribing or claims data more heavily, but that's a different use case than engagement-strategy tiering.

What data does a team need to tier KOLs accurately?

At minimum: publication history, speaking and advisory engagement records, clinical trial or guideline committee involvement, and a record of the company's own interaction history with each KOL. Fragmented or outdated data is the most common reason tiering breaks down in practice.